Routine LDL Exam For Cancer Survivors (LDL Cancer)
Association of Annual LDL Cholesterol Testing With Cardiovascular Outcomes Among Cancer Survivors: A Sequential Target Trial Emulation
This observational study will evaluate whether annual low-density lipoprotein cholesterol (LDL-C) testing is associated with improved cardiovascular preventive care and a lower risk of cardiovascular events among cancer survivors.
The study will use nationwide health insurance and cancer registry data from Korea. Adults with a history of cancer who are alive at least 1 year after cancer diagnosis, have no prior major cardiovascular disease, and are not receiving statin therapy at the start of an eligible study period will be included.
The investigators will compare cancer survivors who undergo LDL-C testing with similar cancer survivors who do not undergo LDL-C testing. Participants will not be assigned to receive testing or treatment by the investigators. Instead, routinely collected health care data will be analyzed.
The main outcome will be major adverse cardiovascular and cerebrovascular events, including cardiovascular death, myocardial infarction, stroke, and coronary revascularization. The study will also examine whether LDL-C testing is associated with subsequent initiation of statin therapy.
The findings may help determine whether routine lipid testing can support cardiovascular disease prevention as part of long-term survivorship care for people with cancer.
研究概览
详细说明
Cardiovascular disease is an important cause of long-term morbidity and mortality among cancer survivors. Current cardio-oncology and survivorship guidelines recommend periodic assessment of cardiovascular risk factors, including lipid profiles. However, limited evidence is available regarding whether routine LDL-C testing leads to greater initiation of preventive therapy or fewer cardiovascular events in cancer survivors.
This nationwide observational cohort study will evaluate the association between annual LDL-C testing and cardiovascular outcomes among statin-naive cancer survivors. The study will use routinely collected administrative health insurance and cancer registry data from Korea.
A sequential target trial emulation design will be used. Eligibility will be reassessed at a series of annual trial baselines beginning 1 year after cancer diagnosis. At each trial baseline, individuals will be eligible if they are alive, remain under observation, have no history of cardiovascular disease, myocardial infarction, stroke, familial hypercholesterolemia, percutaneous coronary intervention, or coronary artery bypass grafting, and are not receiving statin therapy. The same individual may contribute to more than one annual emulated trial if all eligibility criteria continue to be met.
At each eligible trial baseline, participants will be classified according to whether they undergo LDL-C testing. Participants in the active testing group will be compared with participants in the inactive testing group. Propensity scores will be estimated using demographic and clinical variables, including age, sex, cancer type, cancer diagnosis year, cancer stage, hypertension, diabetes mellitus, and dyslipidemia. One-to-one propensity score matching will be performed within each emulated trial.
The primary outcome will be major adverse cardiovascular and cerebrovascular events, defined as a composite of cardiovascular death, myocardial infarction, stroke, and coronary revascularization. Secondary outcomes will include the individual components of the composite outcome and initiation of statin therapy within 1 year after the trial baseline.
For the analysis of statin initiation, participants will be followed for up to 1 year. Follow-up will end at statin initiation, a major cardiovascular event, censoring, or the end of the observation period. For cardiovascular outcome analyses, follow-up will begin at the corresponding annual trial baseline. Participants in the inactive testing group who subsequently undergo LDL-C testing will be censored at the date of testing. Inverse probability-of-censoring weighting will be used in sensitivity analyses to address potential informative censoring.
Hazard ratios and 95% confidence intervals will be estimated using Cox proportional hazards models. Because individuals may contribute to multiple annual emulated trials, robust sandwich variance estimators clustered at the participant level will be used to account for within-person correlation. Competing-risk analyses will account for non-cardiovascular death when evaluating nonfatal cardiovascular outcomes.
Exploratory analyses will evaluate cardiovascular outcomes according to subsequent statin initiation after LDL-C testing. These analyses will be interpreted cautiously because statin use is determined after the trial baseline and is not a randomized treatment assignment. Prespecified subgroup analyses will be conducted according to sex, age, cancer stage, time since cancer diagnosis, cancer type, and diabetes status.
This study is observational. The investigators will not assign LDL-C testing, statin therapy, or any other clinical intervention.
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Individuals with a diagnosis of cancer recorded in the nationwide cancer registry and health insurance database
- Alive and under observation at least 1 year after the initial cancer diagnosis
- Eligible for entry at an annual emulated trial baseline
- Not receiving statin therapy at the corresponding trial baseline
- Available information on age, sex, cancer type, year of cancer diagnosis, cancer stage, diabetes mellitus, hypertension, and dyslipidemia
- Continuous eligibility for outcome ascertainment in the national health insurance database
Exclusion Criteria:
- History of cardiovascular disease before the corresponding trial baseline
- History of myocardial infarction or stroke before the corresponding trial baseline
- History of familial hypercholesterolemia
- History of percutaneous coronary intervention or coronary artery bypass grafting
- Use of statin therapy before or at the corresponding trial baseline
- Missing information required to determine eligibility, exposure status, or prespecified baseline covariates
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Annual LDL-C Testing
Statin-naive cancer survivors who met the eligibility criteria at an annual emulated trial baseline and underwent low-density lipoprotein cholesterol (LDL-C) testing during the prespecified assessment period.
LDL-C testing was identified from routinely collected health insurance claims.
Testing was not assigned by the investigators.
Participants were followed for statin initiation and major adverse cardiovascular and cerebrovascular events.
|
|
No Annual LDL-C Testing
Statin-naive cancer survivors who met the eligibility criteria at an annual emulated trial baseline and did not undergo low-density lipoprotein cholesterol (LDL-C) testing during the corresponding assessment period.
Testing was not assigned by the investigators.
Participants were followed for statin initiation and major adverse cardiovascular and cerebrovascular events.
For cardiovascular outcome analyses, follow-up was censored if LDL-C testing subsequently occurred.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Adverse Cardiovascular and Cerebrovascular Events
大体时间:From each annual emulated trial baseline through up to 6 years of follow-up
|
First occurrence of a composite outcome comprising cardiovascular death, myocardial infarction, stroke, or coronary revascularization.
Cardiovascular outcomes will be identified using prespecified diagnosis, procedure, and mortality records from nationwide health insurance and linked registry data.
Only the first event occurring after each annual emulated trial baseline will be counted for the primary analysis.
|
From each annual emulated trial baseline through up to 6 years of follow-up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Initiation of Statin Therapy
大体时间:Within 1 year after each annual emulated trial baseline
|
Initiation of statin therapy among participants who were not receiving statins at the annual emulated trial baseline.
Statin initiation will be identified from prescription records and defined as the first statin prescription after the trial baseline.
|
Within 1 year after each annual emulated trial baseline
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Routine LDL Exam After Cancer
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.